enGene Therapeutics
Develops non-viral genetic medicines led by a bladder-cancer therapy candidate.
$1.83
After-hours close+0.00 (+0.08%)
At close$1.83(−4.19%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2026 | −$0.47 | — | — |
| Jun 2026 | −$0.48 | −$0.43 | +10.4% |
| Jun 2026 | −$0.48 | −$0.43 | +10.4% |
| Mar 2026 | −$0.55 | −$0.44 | +20.0% |
| Dec 2025 | −$0.57 | −$0.73 | −28.8% |
The latest year is open to everyone — the 15 quarters behind it read with an account. Sign in | |||
| Sep 2025 | |||
| Jun 2025 | |||
| Mar 2025 | |||
| Dec 2024 | |||
| Sep 2024 | |||
| Jun 2024 | |||
| Mar 2024 | |||
| Jan 2024 | |||
| Jul 2023 | |||
| Apr 2023 | |||
| Jan 2023 | |||
| Oct 2022 | |||
| Jul 2022 | |||
| Apr 2022 | |||
| Dec 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | −$0.47 | — | — | — | — | — |
| Jun 15, 2026 | −$0.48 | −$0.43 | +10.4% | — | — | — |
| Jun 11, 2026 | −$0.48 | −$0.43 | +10.4% | — | — | — |
| Mar 9, 2026 | −$0.55 | −$0.44 | +20.0% | — | — | — |
| Dec 22, 2025 | −$0.57 | −$0.73 | −28.8% | — | — | — |
The latest year is open to everyone — the 15 quarters behind it read with an account. Sign in | ||||||
| Sep 11, 2025 | ||||||
| Jun 12, 2025 | ||||||
| Mar 10, 2025 | ||||||
| Dec 19, 2024 | ||||||
| Sep 10, 2024 | ||||||
| Jun 14, 2024 | ||||||
| Mar 11, 2024 | ||||||
| Jan 29, 2024 | ||||||
| Jul 31, 2023 | ||||||
| Apr 30, 2023 | ||||||
| Jan 31, 2023 | ||||||
| Oct 31, 2022 | ||||||
| Jul 31, 2022 | ||||||
| Apr 30, 2022 | ||||||
| Dec 31, 2021 | ||||||